LB-100 is a water-soluble small-molecule inhibitor of protein phosphatase 2A (PP2A) under investigation as a chemo- and radiosensitizing anticancer agent. It is in active clinical trial development for selected solid and hematologic malignancies. Current evidence supports investigational use rather than marketed approval.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06065462 |
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 |
RECRUITING | PHASE1/PHASE2 |
| NCT06012734 |
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients |
RECRUITING | PHASE1 |
| NCT03886662 |
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) |
RECRUITING | PHASE1/PHASE2 |
| NCT03027388 |
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma |
COMPLETED | PHASE2 |
